searchIrbesartanSystematic (IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC avapro 300mg C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic.

Irbesartan/hydrochlorothiazide combination preparations avapro 300mg marketed under similar trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diureticIrbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide avapro 300mg preparations are marketed under avapro 300mg trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl avapro 300mg Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative avapro 300mg Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID avapro 300mg Rossi S, editor. avapro 300mg Medicines Handbook 2006. Adelaide: Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN.

Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN.